Background. The pathogenesis of new onset diabetes after transplantation (NODAT) is multifactorial. Suppression of regulatory T lymphocytes may have a negative impact on pancreatic β-cells. Induction with basiliximab affects regulatory T-cell function and may therefore, theoretically, also affect glucose homeostasis in renal transplant recipients. Results. A total of 264 patients were recruited. One hundred and thirty-four patients received basiliximab. In the basiliximab group, 51.5% developed NODAT, impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) versus 36.9% in the group without induction therapy (P = 0.017). In recipients with normal OGTT, the mean fasting glucose at 10 weeks was 5.18 mmol/l (SD: 0.54) in the basiliximab group (n = 65) and 4.84 mmol/l (SD: 0.64) in the no induction group (n = 82) (P = 0.001).
Introduction
New-onset diabetes mellitus after kidney transplantation (NODAT) is a recognized complication after kidney transplantations [1, 2] . In the literature, the incidence varies from 7 to 45%, depending on time of follow-up, definition of NODAT and chosen diagnostic procedures [3, 4] . Our centre previously reported a NODAT incidence of 20% in kidney recipients [5, 6] . In addition, 30% of the patients developed impaired glucose tolerance during the first 10 weeks after renal transplantation [5, 6] . The incidence has declined in recent years [7] . Several risk factors for NO-DAT have been described; CMV infection [6] , hepatitis C disease [8] , increased body mass index (BMI) [3] , older recipients [5] and immunosuppressive agents such as steroids [9] , calcineurin inhibitors (CNI) [10, 11] and inhibitors of mammalian target of rapamycin (mTOR) [12] . Basiliximab is a CD25 [interleukin (IL)-2] antibody that indirectly suppresses proliferation of T lymphocytes, and thus causes a loss of regulatory T-cells [13] . There is growing evidence that the naturally occurring regulatory T-cells (CD25 + CD4 + Fox3 + cells) control the development of a variety of autoimmune diseases [14] [15] [16] . We hypothesize that basiliximab, by affecting populations of T lymphocytes, indirectly may affect β-cell function leading to impaired glucose homeostasis in patients also receiving steroids and calcineurin inhibitors.
Patients and Methods

Patients
A single-centre retrospective analysis of data from all renal transplantations between 1 January 2005 and through 31 December 2007 was performed. Data from all recipients ≥50 years of age at transplantation were evaluated. Younger recipients were excluded because the immunosuppressive regimen for this age group changed CNI from cyclosporine (CsA) to tacrolimus (Tac) in January 2007.
Before final approval for transplantation, an evaluation of glucose metabolism (an oral glucose tolerance test) is requested in all candidates for kidney transplantation performed at our centre. At 10 weeks post-transplant, a new oral glucose tolerance test was performed. Venous blood samples were taken before and 2 hours after the 75 g dextrose load for immediate analysis of plasma glucose. Diagnosis of diabetes mellitus was defined as a fasting plasma glucose ≥7.0 mmol/l or 2-hour plasma glucose ≥11.1 mmol/l. Impaired glucose tolerance (IGT) was defined as 2-hour plasma glucose ≥7.8 mmol/l and impaired fasting glucose (IFG) fasting plasma glucose ≥6.1 mmol/l (≤7.0 mmol/l) [17] . Glomerular filtration rate (GFR) was assessed by Cr-EDTA.
Immunosuppressive treatment
Standard immunosuppressive protocol from January 2005 to December 2006 consisted of CsA, prednisolone and mycophenolate motefil (MMF). CsA dosage was monitored by C 0 or C 2 measurements. Initial C 0 target was 300-400 μg/l (or C 2 : 1600-2000 μg/l), and then gradually tapered to 100-200 μg/l (C 2 : 800-1200 μg/l) at 10 weeks. C 0 values are presented in the study because they were used throughout the whole study period. Prednisolone, which started at 80 mg/day at Day 1, gradually tapered to 20 mg/day at Day 8, then 15 mg/day from Day 30, and 10 mg/ day from Day 60. Additionally, MMF 1 g bid was administered.
Induction therapy with basiliximab (20 mg i.v. Day 0 and 4) was introduced 1 January 2007. Simultaneously, cyclosporine initial C 0 target was lowered to 150-250 μg/l (or C 2 : 900-1100 μg/l). MMF and steroid dosages remained unchanged.
Acute rejection episodes were treated with 1.25-1.5 g i.v. of methylprednisolone over 4-6 days. Oral steroid dose was increased to 30 mg daily and tapered by 5 mg each 14 days. Anti-thymoglobulin (ATG) and/or muromonab CD3 (OKT-3) were used for steroid-resistant rejections. In this study, acute rejection was defined according to treatment; recipients that were given treatment for rejection were recorded as having acute rejections. However, almost all the rejections were biopsy-verified.
Statistical analysis
Comparisons between groups were performed using analysis of covariance t-tests or Fisher's exact test/ chi-squared test or Mann-Whitney test as appropriate. In order to eliminate the impact of treatment with high steroid doses and everolimus, analyses were, in turn, performed on subgroups of transplant recipients without rejection episodes and without everolimus. Univariate, bivariate and multivariate logistic regression were used to assess odds ratio for developing NODAT, IGT and IFG. In the bivariate analysis, basiliximab was, in turn, analysed with age, sex, fasting p-glucose, 2 hours p-glucose, BMI, living donor (LD)/deceased donor (DD), pre-transplant dialysis, months on waiting list, human leukocyte antigen (HLA) mismatch, p-glucose at admission to hospital, rejection, CMV infection, CsA dose at 10 weeks, total steroid load and weight change. In the final analysis, and presentation, rejection (yes/no) was chosen because rejection episodes were considered to be the cause of the difference in total steroid load between groups, and most strongly interfered with basiliximab in bivariate analysis. Statistics were analysed using SSPS version 16.0.
Results
A total of 699 renal transplantations were performed at our centre from 1 of January 2005 to 31 of December 2007. Among these, 385 renal recipients were ≥50 years of age at transplantation, and 98% were Caucasian. Patients not receiving standard immunosuppression at transplantation (n = 31) or who had known diabetes mellitus (n = 66) were excluded from further analysis. Twenty-four recipients had lacking data at 10 weeks making it impossible to perform valid evaluations. This left us with 264 patients; 130 did not receive induction therapy with basiliximab, and 134 were given basiliximab. Pre-transplant characteristics are presented in Table 1 . Data from the first 10 weeks are presented in Table 2 . (Fig. 1) . Subgroup analysis on patients without rejections (n = 202) and on patients without everolimus (n = 237) showed similar significant differences between the induction and the no induction group (data not shown).
In recipients with normal oral glucose tolerance tests, the mean fasting plasma glucose was higher in the basiliximab group than the no induction group; 5.18 mmol/l (SD: 0.54) vs. 4.84 mmol/l (SD: 0.64) (P = 0.001) (Fig. 2) . Twohour plasma glucose was 5.7 mmol/l (SD: 1.29) and 5.5 mmol/l (SD: 1.22) (P = 0.24).
In the univariate logistic regression analysis, the odds ratio for developing NODAT, IGT or IFG was 1.81 with basiliximab (Table 3) . Bivariate logistic regression analyses identified rejection episodes as the only variable that interfered with basiliximab (bivariate odds ratio for basiliximab adjusted for rejection: 2.00, P = 0.008). In the multiple logistic regression analysis, basiliximab increased the risk of NODAT, IGT and IFG after adjusting for rejection, CMV infection, BMI, age, and pre-transplant p-glucose (Table 3) .
Recipients not receiving basiliximab experienced more rejections. Thus, the oral prednisolone dose at 10 weeks and cumulative steroid load given during the 10 weeks were higher in the no induction patients at the time of as- Due to another study some recipients switched from cyclosporine to everolimus at Week 7.
Impaired glucose homeostasis in renal transplant recipients receiving basiliximabsessment ( Table 2 ). The total dosage of CsA was also higher in the group without induction therapy than in the basiliximab group (Table 2 ). There were no differences between groups neither in cause of end-stage renal disease nor in dropouts.
Discussion
We observed that non-diabetic kidney transplant recipients receiving basiliximab as induction therapy experienced an increased incidence of early NODAT, IGT or IFG in comparison with recipients not receiving induction therapy. It is well-known that use of steroids and CNIs are associated with development of impaired glucose homeostasis following renal transplantation [9, 18, 19] . The reduced steroid load and the lower dose of cyclosporine given to the basiliximab group, in our study, should have favoured reduced incidence of NODAT, IGT and IFG, not the observed increased incidence.
Basiliximab is an antibody directed against the interleukin-2 receptor (CD25) and suppresses CD25 + CD4 + T lymphocytes. T lymphocytes are thought to be involved in the complex immunology causing diabetes type 1 [14, 15] , especially the subgroup of regulatory T lymphocytes; CD25 + CD4 + FOXP3 + cells [16] . There is some evidence that regulatory T-cells play a key role in maintaining immunologic self-tolerance and control the development of a variety of autoimmune diseases [14] [15] [16] . Studies have shown that basiliximab causes a loss of both FOXP3 + and FOXP3 -T cells [13, 20] . Additionally, administration of IL-2 agonists have prevented diabetes mellitus in experimental studies [21] , and neutralization of circulating IL-2 by anti-IL-2 monoclonal antibodies may trigger early onset diabetes and may also cause other cellmediated autoimmune diseases [16] . One could speculate that basiliximab, at least theoretically, may interfere with the immunological balance that stabilizes β-cells and may thus interfere with the function of β-cells in a post-transplant setting.
The major limitation of the study is the retrospective observational design with a historical control group and the short follow-up time. However, we succeeded in including a reasonable number of patients whom were carefully evaluated at one centre over a relative short time-period. The small difference in BMI present at baseline, and the difference in weight gain, in disfavour of the basiliximab group, may contribute to some of the observed negative effects. On the other hand, BMI and percent weight gain did not change the odds ratio of basiliximab in the logistic regression analysis. Unfortunately, we have no information of family history of diabetes mellitus, but presence of a HLA haplotype (B-27) that may predispose for NODAT did not differ between groups [7] . Change in immunosup- pressive treatment during the study (see Table 2 ) may have also influenced the results. The difference between groups in the use of everolimus, which is known to cause NODAT, is of concern. Therefore, subgroup analyses on recipients without everolimus were performed, without affecting the overall results. The number of recipients that switched to tacrolimus, also known to have a more negative effect on glucose homeostasis than CsA [10] , was, however, slightly higher in the basiliximab group, and should have thus had a negative influence on on our findings. After excluding patients with NODAT, IGT and IFG, the remaining kidney recipients in the basiliximab group had higher fasting plasma glucose at 3 months post-transplant than kidney recipients without induction therapy. This finding underlines the possible unfavourable profile of basiliximab described in this study, but the clinical consequence of the finding remains uncertain.
To conclude, we have observed an association between induction therapy with basiliximab and a negative glucose homeostasis in renal transplant recipients. The mechanism remains unknown, and further prospective randomized controlled studies are absolutely necessary to confirm the findings.
